Cost–effectiveness analysis 3L of axicabtagene ciloleucel vs tisagenlecleucel and lisocabtagene maraleucel in Japan
Future Oncology · 2024
DOI: 10.2217/fon-2023-1114 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Future Oncology, 2024. Verfasst von Saaya Tsutsué und 5 weiteren Autor:innen. Beteiligte Einrichtung: Gilead Sciences Japan,1-9-2 Marunouchi, Chiyoda-ku, Tokyo, 100-6616, Japan. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Quality-Adjusted Life Years. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gilead Sciences Japan.
Abstract (Originalsprache)
Aim: Cost-effectiveness analysis (CEA) was performed to compare axicabtagene ciloleucel (axi-cel) with tisagenlecleucel (tisa-cel) and lisocabtagene (liso-cel) for treatment of relapsed or refractory large B-cell lymphoma in adult patients after ≥2 lines of therapy in Japan. Materials & methods: Cost-effectiveness analysis was conducted using the partition survival mixture cure model based on the ZUMA-1 trial and adjusted to the JULIET and TRANSCEND trials using matching-adjusted indirect comparisons. Results & conclusion: Axi-cel was associated with greater incremental life years (3.13 and 2.85) and incremental quality-adjusted life-years (2.65 and 2.24), thus generated lower incremental direct medical costs (-$976.29 [-¥137,657] and -$242.00 [-¥34,122]), compared with tisa-cel and liso-cel. Axi-cel was cost-effective option compared with tisa-cel and liso-cel from a Japanese payer's perspective. [Box: see text].
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gilead Sciences Japan,1-9-2 Marunouchi, Chiyoda-ku, Tokyo, 100-6616, Japan.
- National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
- IQVIA Solutions, Japan, 4-10-18 Takanawa Minato-ku, Tokyo, 108-0074, Japan.
ORCID-Profile: Saaya Tsutsué
Förderung
- Gilead Sciences Japan
Zitieren
APA
Tsutsué, S., Makita, S., Asou, H., Matsuda, H., Yamaura, R., & Taylor, T. D. (2024). Cost–effectiveness analysis 3L of axicabtagene ciloleucel vs tisagenlecleucel and lisocabtagene maraleucel in Japan. Future Oncology. https://doi.org/10.2217/fon-2023-1114
Vancouver
Tsutsué S, Makita S, Asou H, Matsuda H, Yamaura R, Taylor TD. Cost–effectiveness analysis 3L of axicabtagene ciloleucel vs tisagenlecleucel and lisocabtagene maraleucel in Japan. Future Oncology. 2024. doi:10.2217/fon-2023-1114
BibTeX
@article{Tsutsu2024,
author = {Tsutsué, Saaya and Makita, Shinichi and Asou, Hiroya and Matsuda, Hiroyuki and Yamaura, Reiko and Taylor, Todd D},
title = {Cost–effectiveness analysis 3L of axicabtagene ciloleucel vs tisagenlecleucel and lisocabtagene maraleucel in Japan},
journal = {Future Oncology},
year = {2024},
doi = {10.2217/fon-2023-1114}
}
EUVIMED